Precision Begins at
the Proteome
20K+
Human Proteins
1M+
Proteoforms
100%
Patient-Centered
Board
Certified Standard
Pro·te·o·mics
/ ˌprōtēˈōmiks / · noun
noun · precision scienceThe large-scale study of the complete set of proteins expressed by a genome, cell, tissue, or organism at a given time encompassing their structure, function, quantity, and interactions in the context of health and disease.
Origin
From Latin proteinus (protein, first) + Greek -ome (complete set). The term was coined by Marc Wilkins in 1994 to describe the entire protein complement expressed by a genome recognizing that proteins, not genes, are the primary executors of biological function.
The Proteomics Department at the American Board of Precision Medicine bridges the gap between genetic blueprint and biological reality - training clinicians to interrogate the proteome as the functional layer where disease manifests, drug targets reside, and biomarkers are born.
From mass spectrometry-based protein profiling and post-translational modification analysis to structural proteomics and protein-protein interaction mapping, this department equips physicians to interpret the dynamic protein landscape that genomics alone cannot reveal translating proteomic signatures into diagnostic, prognostic, and therapeutic decisions.
Because proteins are the direct mediators of cellular function and the primary targets of most therapeutics, proteomics occupies a uniquely actionable position in the multi-omics stack and at ABOPM, it is taught as the bridge between molecular biology and clinical practice.
20K+
Human Proteins
1M+
Proteoforms
∞
Clinical Possibilities
Where the Proteome Meets
Clinical Purpose
The Proteomics Department at ABOPM exists at the intersection of protein science and patient care - training physicians to decode the proteome, apply its insights, and transform outcomes across every clinical specialty.
Advancing research in mass spectrometry-based protein profiling, post-translational modification analysis, and protein–protein interaction mapping - illuminating the functional molecules that drive cellular processes and disease pathogenesis.
Bridging proteomic laboratory science and bedside medicine developing board-certified frameworks for protein biomarker discovery, targeted therapy selection, and disease monitoring across oncology, autoimmunity, and cardiovascular medicine.
Building the next generation of proteomics-fluent clinicians through rigorous board standards, interdisciplinary training, and collaboration across molecular medicine, oncology, rheumatology, and translational research.
"The proteome is where biology becomes action. The Proteomics Department at ABOPM trains physicians to read that action, interpret its clinical significance, and deliver care that meets patients at the molecular level."
American Board of Precision Medicine · Proteomics DepartmentTranslating the Proteome
Into Clinical Impact
The proteome is where the genome becomes function - the full complement of proteins that execute every biological process in the human body. Learning to read it is not optional for the future of medicine - it is foundational.
Proteomics equips clinicians to move beyond genetic potential and into biological reality - identifying the proteins that drive disease, serve as therapeutic targets, and act as the most direct molecular window into a patient's current health state.
By mastering proteomics, clinicians gain the power to:
Why Proteomics Fluency Is Non-Negotiable
The proteins are active. The clinical tools are ready. The question is, are you?
Proteomics-guided therapy selection improves response rates, reduces toxicity from ill-matched treatments, and enables monitoring of disease at its most functionally relevant molecular level.
Protein-based diagnostics and targeted biologics now dominate oncology and autoimmune pipelines - clinicians who can't interpret proteomic data will be unable to lead the next generation of care.
Board certification in proteomics distinguishes you as a precision medicine leader capable of bridging molecular biology and therapeutic decision-making - a rare and increasingly essential skill set.
Proteomics spans every specialty: oncology, rheumatology, cardiology, neurology, and infectious disease giving you tools to decode disease biology across all of medicine's most complex clinical challenges.
Active research areas driving proteomic medicine forward:
The proteomics revolution is not a future event - it is happening now. Mass spectrometry-based protein profiling, post-translational modification analysis, and single-cell proteomics are actively reshaping how disease is detected, targeted, and monitored at the functional molecular level.
The ABOPM Proteomics Department positions clinicians at the center of this transformation equipping them with the scientific literacy, clinical frameworks, and board-certified credentials to lead proteomic medicine in any specialty.
Meet Our Leadership
Director of Proteomics
Rob Fraser, PhD
Dr. Fraser is President, Chief Scientific Officer, and Co-founder of Molecular You Corporation, where he leads scientific strategy behind a multi-biomarker analytics platform. As founding CEO, he pioneered a cost-effective method to quantify hundreds of biomarkers from a single blood sample and integrate them with AI-enabled literature insights.
His training includes the University of Alberta, Harvard Medical School, and postdoctoral fellowships in Toronto and Strasbourg. He has held senior research roles at Sanofi, Xenon, Neuromed, and CDRD, and co-founded multiple companies including GenXys Health Care Systems, Mesentech Corporation, Contextual Genomics, and Microbiome Insights.
He has helped raise more than $50 million to support health tech ventures and continues to focus on translating science into clinically actionable tools. A former varsity swimmer and member of the Canadian National Water Polo Team, he remains active in philanthropy and health innovation.
Ash Anwar, PhD
Ash is a Co-founder and Senior Director of Scientific Innovation at Molecular You, where he drives strategic partnerships and scales AI-driven clinical platforms. With over a decade at the intersection of precision health and artificial intelligence, he has a proven track record in de novo venture creation and translating research into real-world impact.
His academic training spans Simon Fraser University (BSc Honours, Molecular Biology & Biochemistry), a Research Fellowship at Harvard Medical School (Schepens Eye Research Institute), a PhD in Experimental Medicine from UBC (Djavad Mowafaghian Centre for Brain Health), and an MBA from UBC's Sauder School of Business. He has also served as an Instructor of Business Analytics at University Canada West.
As co-founder of USHA, he led deployment of a national maternal care health app, and at EvenCare helped secure $1M in seed funding through strategic storytelling and validated product-market fit.
Faculty Members
Our faculty roster is growing - announcements coming soon.
Faculty position open
Faculty position open
Faculty position open
Faculty position open
Think you're the right fit for a faculty position?
Get Involved →
Shaping the Future
of Precision Medicine
As precision medicine continues to evolve, genomics will play an increasingly central role in redefining how disease is understood, predicted, and treated at the molecular level.
The Genomics Department at ABOPM remains committed to advancing this field through scientific leadership, clinical innovation, and collaborative discovery. Together with our global community of physicians and researchers, we are helping shape the future of next-generation healthcare.
Insights Shaping
Precision Medicine
Explore ABOPM perspectives on genomics, multi-omics, systems thinking, clinical innovation, and the future of physician leadership in precision medicine.
Liquid Biopsy and Early Cancer Detection: Promise and Limitations
Liquid biopsy is transforming cancer detection through minimally invasive genomic testing, offering new opportunities for earlier diagnosis and monitoring. ...more
Precision Oncology
June 05, 2026•9 min read
Polygenic Risk Scores and the Genomic Data Gap: Promise, Limitations, and Equity in Precision Medicine
Polygenic risk scores may transform disease prediction, but gaps in genomic diversity continue to limit equity, accuracy, and access in precision medicine across global populations. ...more
Population Precision
May 26, 2026•9 min read
Artificial Intelligence in Precision Medicine
Artificial intelligence is reshaping precision medicine by improving diagnostics, predicting treatment response, and enabling more personalized, data-driven healthcare strategies. ...more
On the Frontier
May 20, 2026•9 min read
Stay at the Forefront of Precision Medicine
Subscribe to receive ABOPM insights, research updates, and educational resources delivered directly to your inbox.
Advancing education, certification, and leadership to shape a genomics-driven, data-intelligent future of healthcare.
COMPANY
RESOURCES
© 2023-2025 American Board of Precision Medicine, Inc. All Rights Reserved.